Showing 1441-1450 of 1614 results for "".
- Uplinza Approved in Japan for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/uplinza-approved-in-japan-for-the-prevention-of-relapses-of-neuromyelitis-optica-spectrum-disorder-nmosd/2479009/Horizon Therapeutics announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval of Uplinza for the prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica) from the Japanese Ministry o
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- Remembering Ophthalmic Industry Executive George Marcellinohttps://modernod.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/Ophthalmic industry executive George Marcellino, PhD, whose work lead to the development of several new technologies and medical devices, died on February 10, 2021. Most recently, Dr. Marcellino served as vice president of clinical affairs and marketing at Iridex. On its website, Iridex posted th
- Ophthalmic Fundraising Activity Soars in Face of Pandemichttps://modernod.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion, according to a new Market Scope report. Retina is the largest ophthalmic market sector, driven by a booming pharma
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- Heine Announces Launch of Omega 600 Lightweight Indirect Ophthalmoscopehttps://modernod.com/news/heine-announces-launch-of-new-omega-600-lightweight-indirect-ophthalmoscope/2478842/Heine has launched its newest indirect ophthalmoscope, the Omega 600. The Omega 600 includes a new design that makes it the lightest high-end indirect on the market courtesy of a new ultralight battery, according to Heine. Other new features are Heine’s visionBOOST technology, which is des
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- EU Authorizes AstraZeneca’s COVID-19 Vaccine Amid Supply Disputehttps://modernod.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/The European Commission on Friday granted a conditional marketing authorization to AstraZeneca and the University of Oxford’s AZD1222 for people aged 18 years and older, making it the third COVID-19 vaccine authorized in the EU, following Pfizer and BioNTech’s vaccine Comirnaty, as we
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai
- NTC Grants to Zhaoke Exclusive License and Distribution Rights in Asia for NTC014 for Bacterial Conjunctivitishttps://modernod.com/news/ntc-grants-to-zhaoke-exclusive-license-and-distribution-rights-in-asia-for-ntc014-for-bacterial-conjunctivitis/2478758/Italy-based NTC and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited announced an agreement for exclusive license and distribution rights of NTC014 fixed combination of a quinolone antibiotic and a NSAID in eye drops. Zhaoke will market NTC014 in